menu search

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that two abstracts detailing vebreltinib data were made available as part of the European Society of Medical Oncology Congress (ESMO) 2023 being […] The post Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023... Read More
Posted: Oct 16 2023, 22:55
Author Name: forextv
Views: 082411

Search within

Pages Search Results: